Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | LIPC | P11150 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21578063 | 0.93 | SLC7A5 (0.58) | SLC7A5PTGS2FOLH1CYP4F2CYP4A11 | |
| SCHEMBL20179262 | 0.87 | SLC7A5 (0.49) | SLC7A5PTGS2CTSBCTSSCTSK | |
| SCHEMBL20179266 | 0.87 | SLC7A5 (0.47) | SLC7A5PTGS2CTSBCTSSCTSK | |
| SCHEMBL21578143 | 0.84 | SLC7A5 (0.56) | SLC7A5PTGS2CTSBCTSSCTSK | |
| SCHEMBL21578011 | 0.84 | FOLH1 (0.46) | PTGS2FOLH1BCL2 | |
| SCHEMBL21578054 | 0.81 | SLC7A5 (0.39) | SLC7A5CYP4F2CYP4A11 | |
| SCHEMBL24023444 | 0.81 | SLC7A5 (0.46) | SLC7A5PTGS2NR1H2NR1H3RXRA | |
| SCHEMBL20179248 | 0.80 | SLC7A5 (0.56) | SLC7A5FOLH1CYP4F2CYP4A11 | |
| SCHEMBL21570577 | 0.79 | FOLH1 (0.49) | SLC7A5CTSBCTSSCTSKFOLH1 | |
| SCHEMBL20168766 | 0.79 | FOLH1 (0.49) | SLC7A5CTSBCTSSCTSKFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2021-11-18 | — | — | US | disclosed |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | GPI, TPI1, HPGDS | SLC7A5 505/4885PTGS2 573/4885CTSB 685/4885 |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | TPI1, HPGDS, GPI | SLC7A5 463/4885PTGS2 441/4885CTSB 622/4885 |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | GLS, HPGDS, GPI | SLC7A5 536/4885PTGS2 610/4885CTSB 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.